Promoting transparency to avoid costly healthcare mistakes – the CHEER…

22/05/2013

Donald Husereau

Donald Husereau highlights the benefits of the recent CHEERS guidelines to biomedical publishing. More than ever, rising healthcare costs have led to the need for good healthcare decisions. Yet the information...

Promoting research, innovation and competition: the reform of the clin…

22/05/2013

Catherine McLoughlin

With changes proposed to the clinical trials regime in the EU, we look at the principal changes being considered and assess their potential impact on the conduct of research and...

How doctors prefer to engage with pharma: part three

21/05/2013

Doctor C

 In part of three of this series, Hannah Blake interviews an oncologist (who will be referred to as Doctor C) about his thoughts on the interaction between physicians and pharma. (Continued...

Digital health perspectives: Francesco Raimo

21/05/2013

Francesco Raimo

pharmaphorum's Rebecca Aris caught up with the Digital Director of Life Healthcare Communications, Francesco Raimo, to hear his views on digital in healthcare. Francesco Raimo comes from a technical background, as...

Novo acquires Xellia Pharma for $700m

22/05/2013

Hannah Blake

Novo A/S has announced its acquisition of Xellia Pharmaceuticals for US $700 million. Novo A/S is the holding company of the Novo Group, which is the major shareholder in Danish pharma...

GSK given $200m to develop antibiotics

22/05/2013

Hannah Blake

The US Department of Health and Human Services (HHS) has entered into a first-of-its-kind collaboration with GSK, whereby the HHS' Biomedical Advanced Research and Development Authority (BARDA) provide GSK with...

Phase 2 trials show Sanofi, Regeneron drug reduces risk of asthma atta…

21/05/2013

Hannah Blake

Postive phase 2 clinical trial data of Sanofi and Regeneron's asthma treatment, dupilumab, have today been published in the New England Journal of Medicine. The study found that dupilumab (Sis...

Bayer reports positive phase 3 data for lung drug

21/05/2013

Hannah Blake

Bayer has announced positive data from the interim analysis of its experimental riociguat drug to treat patients with pulmonary arterial hypertension (PAH). In the extension of a phase 3 clinical trial,...

Open access in medical journals - interv…

Executive perspectives: Bruno Strigini

Doctors hold the key to understanding pa…

Carly Brown

Pharma is recognising the increasing importance of the patient voice in providing feedback on how medicines are utilised in a real-world setting and the impact they are having on outcomes....

Outcomes shape the new payer networks fo…

Marcelo Fantoni

The definition of the payer and the way in which healthcare spending decisions are made is changing, as complex networks of payers and clinicians become the new stakeholders with which...

Publishing white papers on pharmaphorum

Paul Tunnah

As a new feature on pharmaphorum, we unveil pharmaceutical industry white papers as part of our media section. Download this one page document to understand how to publish your deep...